Alzheimer's disease (AD) is a global health concern owing to its complexity, which often poses a great challenge to the development of therapeutic approaches. No single theory has yet accounted for the various risk factors leading to the pathological and clinical manifestations of dementia-type AD. Therefore, treatment options targeting various molecules involved in the pathogenesis of the disease have been unsuccessful. However, the exploration of various immunotherapeutic avenues revitalizes hope after decades of disappointment. The hallmark of a good immunotherapeutic candidate is not only to remove amyloid plaques but also to slow cognitive decline. In line with this, both active and passive immunotherapy have shown success and limitati...
Alzheimer’s disease (AD) is a disorder of brain which progressively weakens the cognitive function. ...
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of de...
There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease ...
Abstract Only a small percentage of patients with Alzheimer's disease benefit from current drug ther...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologi...
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of de...
Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 m...
Kuniko Kohyama,1 Yoh Matsumoto2–4 1Department of Brain Development and Neural Regeneration, To...
The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The exact mechanisms leading to Alzheimer's disease (AD) are largely unknown, limiting the identific...
The success of active and passive anti-Aβ immunotherapies in both preventing and clearing parenchyma...
Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide and is an emerging global ...
The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), incre...
International audienceResults of Phase III studies involving a large number of Alzheimer's disease (...
Alzheimer’s disease (AD) is a disorder of brain which progressively weakens the cognitive function. ...
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of de...
There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease ...
Abstract Only a small percentage of patients with Alzheimer's disease benefit from current drug ther...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologi...
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of de...
Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 m...
Kuniko Kohyama,1 Yoh Matsumoto2–4 1Department of Brain Development and Neural Regeneration, To...
The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The exact mechanisms leading to Alzheimer's disease (AD) are largely unknown, limiting the identific...
The success of active and passive anti-Aβ immunotherapies in both preventing and clearing parenchyma...
Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide and is an emerging global ...
The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), incre...
International audienceResults of Phase III studies involving a large number of Alzheimer's disease (...
Alzheimer’s disease (AD) is a disorder of brain which progressively weakens the cognitive function. ...
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of de...
There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease ...